by Eclosion Team | Feb 20, 2018 | Uncategorized
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in a preclinical model showed that GKT831, the Company’s NOX1 and NOX4 inhibitor, efficiently targeted cancer...
by Eclosion Team | Jan 9, 2018 | Uncategorized
Geneva, Switzerland, January 9, 2018 – 6:00 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type 1 diabetes (T1D), announced...
by Eclosion Team | Oct 28, 2017 | Uncategorized
Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNbAC1 for the treatment of patients with...
by Eclosion Team | Sep 11, 2017 | Uncategorized
Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that data supporting the role of pathogenic pHERV-W env in Type 1...
by Eclosion Team | Aug 28, 2017 | Uncategorized
Geneva, Switzerland, and Paris, France, 28 August 2017 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today 6-month results from the 12-month CHANGE-MS Phase 2b study of three doses of GNbAC1 for the treatment of patients with...
by Eclosion Team | Aug 3, 2017 | Uncategorized
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in multiple preclinical models showed that GKT831, the Company’s NOX1 and NOX4 inhibitor, efficiently targeted...